C-terminal is developed in rabbit using as
immunogen a synthetic peptide corresponding to amino
acids 411-425 of human RbAp46, conjugated to KLH
via an N-terminal added cysteine residue. The
immunizing peptide
RbAp46 is developed in rabbit using as
immunogen a synthetic peptide corresponding to amino
acids 413-425 of human RbAp48, conjugated to KLH
via an N-terminal added lysine residue. The immunizing
peptide
per minute at pH 8.8 at 25 °C.
Protein: ≥90% (UV absorbance)
Extinction coefficient:5 E1% = 14.6 (water, 280 nm)
Precautions and Disclaimer
This product is for R&D use only, not for drug,
household
EDTA, pH approx. 8.0)
E5650 60 ml 280 ml
GenElute Maxiprep Binding Columns in
Tubes
G6665 10 each 5 x 10 each
Collection Tubes, 50 ml capacity C4353 10 each 5 x 10 each
of large multiprotein complexes of coactivators or core-
pressors, respectively.2, 7 RbAp48 is a 425 amino acids
WD-domain protein isolated as a RB1 (retinoblas toma
binding protein). RbAp46 (also known
of large multiprotein complexes of coactivators or core-
pressors, respectively.2, 7 RbAp48 is a 425 amino acids
WD-domain protein isolated as a RB1 (retinoblas toma
binding protein). RbAp46 (also known
hole cap (10-425 thread), large opening, pre-assembled volume 2 mL, clear glass vial,
red PTFE/silicone septum, pkg of 100
27531
Vials, screw top with black polypropylene hole cap (10-425 thread)
* * 1210 50 10
Transthyretin * 425 5 253
Apo-CIII * 1400 370 9
Apo B * 358 130 n/a
% of total protein amount for flow-through
Reproducibility (CV of flow-through@280 nm)
Protein Name LTQ #scans
.
Absorption and emission spectra of CF405S conjugated
to goat anti-mouse IgG in PBS.
325 375 425 475 525
Wavelength (nm)
A
bs
or
pt
io
n Em
ission
Precautions and Disclaimer
This product
.
Absorption and emission spectra of CF405S conjugated
to goat anti-mouse IgG in PBS.
325 375 425 475 525
Wavelength (nm)
A
bs
or
pt
io
n Em
ission
Precautions and Disclaimer
This product
solids may be observed.
Experimental: 75 µL of a 10 mg/mL solution of antibody is dissolved in 425 µL PBS (phosphate buffer
saline, pH = 7.4). 100 µL of this antibody solution is placed in a cuvette
Derivation of clinically compliant MSCs from CD105+, CD24-
differentiated human ESCs. Stem Cells 25:425–436.
15. Olivier EN, Rybicki AC, Bouhassira EE (2006) Differentiation of human embryonic stem
cells
276, 38837-38843 (2001).
74. Kaeberlein, M., et al., J. Biol. Chem., 280, 17038-17045 (2005).
75. Howitz, K.T., et al., Nature, 425, 191-196 (2003).
Te
ch
n
ic
a
l
A
rt
ic
le
y
423 MAP Kinase, Monophosphorylated Threonine M3557 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
425 MAP Kinase (ERK1+ERK2) M5670 5594 MAPK1 P NP_002736.3,NP_620407.1 , y y y
428 MAPK non phosphorylated
y
423 MAP Kinase, Monophosphorylated Threonine M3557 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
425 MAP Kinase (ERK1+ERK2) M5670 5594 MAPK1 P NP_002736.3,NP_620407.1 , y y y
428 MAPK non phosphorylated
y
423 MAP Kinase, Monophosphorylated Threonine M3557 5594 MAPK1 M NP_002736.3,NP_620407.1 , y y y
425 MAP Kinase (ERK1+ERK2) M5670 5594 MAPK1 P NP_002736.3,NP_620407.1 , y y y
428 MAPK non phosphorylated
198-207 (2003).
4. Dreisewerd, K., The desorption process in MALDI. Chem. Rev., 103,
395-425 (2003).
5. Karas, M., and Krüger, R., Ion formation in MALDI. Chem. Rev., 103,
427-439 (2003).
6.
y
423 MAP Kinase, Monophosphorylated Threonine M3557 M y y y
424 MAP Kinase (ERK-1) M7927 P y y y
425 MAP Kinase (ERK1+ERK2) M5670 P y y y
426 MAP Kinase Activated Protein Kinase-2 (MAPKAPK-2) M3550 P
MAP Kinase (ERK-1) M7927 50689, 26417, 5595 MAPK3,Mapk3 NP_059043.1,NP_036082.1,NP_002737.2 P y y y
425 MAP Kinase (ERK1+ERK2) M5670 50689, 26417, 5595 MAPK3,Mapk3 NP_059043.1,NP_036082.1,NP_002737.2 P y
MAP Kinase (ERK-1) M7927 50689, 26417, 5595 MAPK3,Mapk3 NP_059043.1,NP_036082.1,NP_002737.2 P y y y
425 MAP Kinase (ERK1+ERK2) M5670 50689, 26417, 5595 MAPK3,Mapk3 NP_059043.1,NP_036082.1,NP_002737.2 P y